E
Sirona Biochem Corp.
SRBCF
$0.0418
$0.00010.24%
E
Sell
2/24/2025Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 2/24/2025 due to a decline in the volatility index and valuation index.
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 2/24/2025 due to a decline in the volatility index and valuation index.
D
Sell
2/5/2025Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 2/5/2025 due to an increase in the volatility index and total return index.
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 2/5/2025 due to an increase in the volatility index and total return index.
E
Sell
1/21/2025Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 1/21/2025 due to a decline in the volatility index.
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 1/21/2025 due to a decline in the volatility index.
D
Sell
1/6/2025Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 1/6/2025 due to an increase in the volatility index.
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 1/6/2025 due to an increase in the volatility index.
E
Sell
11/7/2024Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 11/7/2024 due to a decline in the volatility index.
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 11/7/2024 due to a decline in the volatility index.
D
Sell
10/23/2024Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 10/23/2024 due to an increase in the volatility index and total return index.
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 10/23/2024 due to an increase in the volatility index and total return index.
E
Sell
10/3/2024Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 10/3/2024 due to a large decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.0012 to -$0.0025, total revenue declined 76.83% from $8.2 to $1.9, and EBIT declined 70.64% from -$281.7 to -$480.7.
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 10/3/2024 due to a large decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.0012 to -$0.0025, total revenue declined 76.83% from $8.2 to $1.9, and EBIT declined 70.64% from -$281.7 to -$480.7.
D
Sell
9/25/2024Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 9/25/2024 due to an increase in the volatility index.
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 9/25/2024 due to an increase in the volatility index.
E
Sell
9/6/2024Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 9/6/2024 due to a decline in the volatility index and valuation index.
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 9/6/2024 due to a decline in the volatility index and valuation index.
D
Sell
8/20/2024Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 8/20/2024 due to an increase in the volatility index, total return index and valuation index.
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 8/20/2024 due to an increase in the volatility index, total return index and valuation index.
E
Sell
8/1/2024Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 8/1/2024 due to a decline in the volatility index and growth index.
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 8/1/2024 due to a decline in the volatility index and growth index.
D
Sell
7/17/2024Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 7/17/2024 due to an increase in the volatility index.
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 7/17/2024 due to an increase in the volatility index.
E
Sell
6/26/2024Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 6/26/2024 due to a decline in the solvency index, volatility index and valuation index. The quick ratio declined from 0.37 to 0.34.
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 6/26/2024 due to a decline in the solvency index, volatility index and valuation index. The quick ratio declined from 0.37 to 0.34.
D
Sell
6/17/2024Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 6/17/2024 due to an increase in the volatility index and valuation index.
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 6/17/2024 due to an increase in the volatility index and valuation index.
E
Sell
10/23/2023Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 10/23/2023 due to a decline in the volatility index and total return index.
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 10/23/2023 due to a decline in the volatility index and total return index.
D
Sell
10/6/2023Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 10/6/2023 due to a large increase in the growth index, volatility index and total return index. EBIT increased 38.44% from -$532.8 to -$328, operating cash flow increased 27.91% from -$560.8 to -$404.3, and earnings per share increased from -$0.0022 to -$0.0016.
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 10/6/2023 due to a large increase in the growth index, volatility index and total return index. EBIT increased 38.44% from -$532.8 to -$328, operating cash flow increased 27.91% from -$560.8 to -$404.3, and earnings per share increased from -$0.0022 to -$0.0016.
E
Sell
9/28/2023Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 9/28/2023 due to a decline in the total return index and volatility index.
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 9/28/2023 due to a decline in the total return index and volatility index.
D
Sell
9/8/2023Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 9/8/2023 due to an increase in the volatility index, growth index and valuation index.
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 9/8/2023 due to an increase in the volatility index, growth index and valuation index.
E
Sell
7/10/2023Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 7/10/2023 due to a decline in the volatility index, growth index and solvency index. Operating cash flow declined 248.97% from -$160.7 to -$560.8, EBIT declined 22.6% from -$434.6 to -$532.8, and earnings per share declined from -$0.0018 to -$0.0022.
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 7/10/2023 due to a decline in the volatility index, growth index and solvency index. Operating cash flow declined 248.97% from -$160.7 to -$560.8, EBIT declined 22.6% from -$434.6 to -$532.8, and earnings per share declined from -$0.0018 to -$0.0022.
D
Sell
6/16/2023Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 6/16/2023 due to a large increase in the growth index, valuation index and total return index. Operating cash flow increased 42.69% from -$280.4 to -$160.7.
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 6/16/2023 due to a large increase in the growth index, valuation index and total return index. Operating cash flow increased 42.69% from -$280.4 to -$160.7.
E
Sell
3/6/2023Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 3/6/2023 due to a large decline in the solvency index, growth index and valuation index. Debt to equity increased from 0.58 to 2.22, total revenue declined 97.32% from $508.2 to $13.6, and the quick ratio declined from 2.41 to 1.41.
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 3/6/2023 due to a large decline in the solvency index, growth index and valuation index. Debt to equity increased from 0.58 to 2.22, total revenue declined 97.32% from $508.2 to $13.6, and the quick ratio declined from 2.41 to 1.41.
D
Sell
2/23/2023Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
Sirona Biochem Corp. (SRBCF) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 2/8/2023 due to a large decline in the total return index, volatility index and valuation index.
Sirona Biochem Corp. (SRBCF) was downgraded to E+ from D- on 2/8/2023 due to a large decline in the total return index, volatility index and valuation index.
D
Sell
5/23/2022Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to D- from D on 5/23/2022 due to a decline in the total return index and volatility index.
Sirona Biochem Corp. (SRBCF) was downgraded to D- from D on 5/23/2022 due to a decline in the total return index and volatility index.
D
Sell
5/5/2022Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index.
Sirona Biochem Corp. (SRBCF) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index.
D
Sell
4/20/2022Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to D- from D on 4/20/2022 due to a significant decline in the growth index and solvency index. Earnings per share declined from -$0.001 to -$0.0071, EBIT declined 554.52% from -$241.4 to -$1.58M, and operating cash flow declined 265.61% from -$173.9 to -$635.8.
Sirona Biochem Corp. (SRBCF) was downgraded to D- from D on 4/20/2022 due to a significant decline in the growth index and solvency index. Earnings per share declined from -$0.001 to -$0.0071, EBIT declined 554.52% from -$241.4 to -$1.58M, and operating cash flow declined 265.61% from -$173.9 to -$635.8.
D
Sell
11/23/2021Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D from D- on 11/23/2021.
Sirona Biochem Corp. (SRBCF) was upgraded to D from D- on 11/23/2021.
D
Sell
11/8/2021Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the total return index, volatility index and solvency index. Debt to equity increased from -3.08 to -1.39, and the quick ratio declined from 1.47 to 1.05.
Sirona Biochem Corp. (SRBCF) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the total return index, volatility index and solvency index. Debt to equity increased from -3.08 to -1.39, and the quick ratio declined from 1.47 to 1.05.
D
Sell
7/2/2021Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to D from D+ on 7/2/2021 due to a major decline in the total return index, growth index and solvency index. Earnings per share declined from -$0.0023 to -$0.0029, EBIT declined 15.59% from -$495.1 to -$572.3, and the quick ratio declined from 1.57 to 1.47.
Sirona Biochem Corp. (SRBCF) was downgraded to D from D+ on 7/2/2021 due to a major decline in the total return index, growth index and solvency index. Earnings per share declined from -$0.0023 to -$0.0029, EBIT declined 15.59% from -$495.1 to -$572.3, and the quick ratio declined from 1.57 to 1.47.
D
Sell
5/26/2021Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D+ from D on 5/26/2021 due to a substantial increase in the growth index, total return index and valuation index.
Sirona Biochem Corp. (SRBCF) was upgraded to D+ from D on 5/26/2021 due to a substantial increase in the growth index, total return index and valuation index.
D
Sell
4/1/2020Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D from D- on 4/1/2020 due to a major increase in the solvency index, efficiency index and valuation index. The quick ratio increased from 4.56 to 9.37, and debt to equity declined from 0.66 to 0.46.
Sirona Biochem Corp. (SRBCF) was upgraded to D from D- on 4/1/2020 due to a major increase in the solvency index, efficiency index and valuation index. The quick ratio increased from 4.56 to 9.37, and debt to equity declined from 0.66 to 0.46.
D
Sell
10/1/2019Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to D- from D+ on 10/1/2019 due to a major decline in the total return index, growth index and valuation index. Earnings per share declined from -$0.005 to -$0.0075, and EBIT declined 6.25% from -$891.2 to -$946.9.
Sirona Biochem Corp. (SRBCF) was downgraded to D- from D+ on 10/1/2019 due to a major decline in the total return index, growth index and valuation index. Earnings per share declined from -$0.005 to -$0.0075, and EBIT declined 6.25% from -$891.2 to -$946.9.
D
Sell
7/1/2019Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D+ from D- on 7/1/2019 due to a significant increase in the total return index and volatility index.
Sirona Biochem Corp. (SRBCF) was upgraded to D+ from D- on 7/1/2019 due to a significant increase in the total return index and volatility index.
D
Sell
10/2/2018Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to D- from D on 10/2/2018 due to a decline in the efficiency index, solvency index and valuation index.
Sirona Biochem Corp. (SRBCF) was downgraded to D- from D on 10/2/2018 due to a decline in the efficiency index, solvency index and valuation index.
D
Sell
9/4/2018Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D from D- on 9/4/2018 due to an increase in the total return index, volatility index and valuation index.
Sirona Biochem Corp. (SRBCF) was upgraded to D from D- on 9/4/2018 due to an increase in the total return index, volatility index and valuation index.
D
Sell
8/17/2018Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to D- from D on 8/17/2018 due to a decline in the total return index and volatility index.
Sirona Biochem Corp. (SRBCF) was downgraded to D- from D on 8/17/2018 due to a decline in the total return index and volatility index.
D
Sell
6/28/2018Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D from D- on 6/28/2018 due to an increase in the efficiency index and valuation index.
Sirona Biochem Corp. (SRBCF) was upgraded to D from D- on 6/28/2018 due to an increase in the efficiency index and valuation index.
D
Sell
11/2/2017Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to D- from D on 11/2/2017 due to a decline in the volatility index and total return index.
Sirona Biochem Corp. (SRBCF) was downgraded to D- from D on 11/2/2017 due to a decline in the volatility index and total return index.
D
Sell
10/18/2017Upgraded
Sirona Biochem Corp. (SRBCF) was upgraded to D from D- on 10/18/2017 due to an increase in the valuation index and growth index. Total revenue increased 325% from $400 to $1.7, EBIT increased 11.48% from -$494.7 to -$437.9, and earnings per share increased from -$0.0032 to -$0.0029.
Sirona Biochem Corp. (SRBCF) was upgraded to D from D- on 10/18/2017 due to an increase in the valuation index and growth index. Total revenue increased 325% from $400 to $1.7, EBIT increased 11.48% from -$494.7 to -$437.9, and earnings per share increased from -$0.0032 to -$0.0029.
D
Sell
3/11/2016Downgrade
Sirona Biochem Corp. (SRBCF) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, solvency index and valuation index.
Sirona Biochem Corp. (SRBCF) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, solvency index and valuation index.
OTC PK
03/05/2025 3:16PM Eastern
Quotes delayed
